Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS, Director of the Program in Health Equity Innovation at the Penn Center for Cancer Care Innovation (PC3I), is leading a collaborative research initiative with Gilead Sciences, Inc. to optimize the collection of social and behavioral determinants of health data from patients receiving breast cancer care at Penn Medicine.
Launching today, the project will bring together an interdisciplinary team comprised of researchers across multiple departments and disciplines at Penn Medicine, experts in the collection of social and behavioral determinants of health data, survivors of breast cancer, and experts from Gilead Sciences, Inc. The study will test which of three channels for patient engagement is best for collecting patient-reported outcome measures (PROMs) that cover social and behavioral determinants of health: a bidirectional text chatbot; the patient portal via their electronic health record; and via telephone. Mixed-methods practice-based research will evaluate the impact of the social and behavioral determinants of health data collection linked with community-based interventions to address stressors.
Learn more about this innovative project.
PC3I and Tennessee Oncology’s McKay Institute for Oncology Transformation Unveil New Collaborative Relationship
PC3I and Tennessee Oncology’s McKay Institute for Oncology Transformation announce an academic-community oncology innovation partnership to improve cancer care delivery.
PC3I Associate Director Surbhi Grover and Deputy Director Katharine Rendle presented research at the 14th AORTIC International Conference on Cancer in Africa, which took place in Dakar, Senegal.
Through the Innovation Accelerator, the Penn Center for Cancer Care Innovation (PC3I) at the Abramson Cancer Center (ACC) invite applications for initiatives that aim to create and test innovative solutions to address challenges in productivity, efficiency, clinician wellbeing, or access in cancer care at Penn Medicine